AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection
Published: 16 November 2023
-
Views:
2166
-
Likes:
7
-
Views:
2166
-
Likes:
7
-
Up Next -
16m 5sPart 1 | Session 3 MINT: Myocardial Ischaemia & Transfusion -
11m 41sPart 1 | Session 4 KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension -
8m 35sPart 1 | Session 5 CordiO App: Speech Analysis to Detect Worsening HF in ADHF Patients -
14m 32sPart 1 | Session 6 AHA23: Presidential Advisory on Cardiovascular-Kidney-Metabolic Health -
10m 36sPart 1 | Session 7 AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF -
9m 14sPart 1 | Session 8 An Extended Duration Short-Interfering RNA Targeting Lp(a) -
11m 15sPart 1 | Session 9 ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin -
15m 26sPart 1 | Session 10 ARIES HM3: Avoidance of Aspirin with LVAD Devices
-
14m 58sPart 1 | Session 1 ORBITA-2: PCI for Stable Angina Rasha Al-Lamee, Nazli Okumus, Christopher Rajkumar
Overview
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.
These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
More from this programme
Part 1
Radcliffe & Cardionerds @AHA23
About the episode
AHA 2023 - Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) is interviewed by Dr Ahmed Ghoneem (UPMC Harrisburg, US), CardioNerds Ambassador, on the findings of the SELECT Trial.
SELECT is a randomised trial aiming to determine if semaglutide can reduce the risk of cardiovascular events in patients with overweight or obesity and prior cardiovascular disease. 17609 patients were enrolled in the trial, and were randomized to receive either semaglutide or placebo.
The once-weekly subcutaneous injection of semaglutide 2.4 mg resulted in a 20% reduction in the risk of cardiovascular death, myocardial infarction (MI) or stroke. This benefit was observed early and consistently across various subgroups and cardiovascular endpoints.
Recorded on-site at AHA 2023, Philadelphia.
Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
Faculty Biographies
A Michael Lincoff
Dr A. Michael Lincoff, MD, assumes the role of Vice Chairman within the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, acting as an interventional cardiologist at the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic.
With a purview extending beyond clinical practice, Dr Lincoff spearheads clinical research endeavours throughout the Cleveland Clinic as the Director of the Center for Clinical Research at the Lerner Research Institute. He is also at the helm of the Cleveland Clinic Coordinating Center for Clinical Research (C5Research), an academic research organization dedicated to planning, coordinating, and managing multicenter clinical trials exploring new pharmacologic or device therapies.
Dr Lincoff's research endeavours are concentrated on advancing therapies aimed at mitigating acute and long-term complications of percutaneous coronary revascularization procedures. Additionally, his work seeks to…
Ahmed Ghoneem
Ahmed Ghoneem is a first year cardiology fellow at UPMC (Harrisburg) and served as a CardioNerds Conference Scholar for the American Heart Association 2023 Scientific Sessions.
Comments